---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-219422"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2026-05-12T20:10:17+00:00"
generated_at: "2026-05-12T21:07:48.687593+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology Q1 2026: $5.8M KOMZIFTI net revenue in first full commercial quarter; cash $580.8M

## Summary
- Net product revenue $5.8M from KOMZIFTI in first full commercial quarter; 85 new patient starts, 157 total prescriptions.
- Net loss $73.3M (Q1 2025: $57.4M); R&D expense $65.3M, SG&A $31.6M on commercialization investments.
- Cash $580.8M plus $180M anticipated Kyowa Kirin payments expected to fund ziftomenib program through 2028.
- Payer coverage >93% across >12M lives; early adoption includes repeat use, switching from other menin inhibitors.
- Multiple 2026 catalysts: EHA updated KOMET-007 data, ASCO darlifarnib/adagrasib data, KOMET-008 preliminary data.

## SEC filing metadata
- accession: 0001193125-26-219422
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2026-05-12T20:10:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312526219422/0001193125-26-219422-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312526219422/kura-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-219422
- JSON: https://secwatch.observer/filing/0001193125-26-219422.json
- Plain text: https://secwatch.observer/filing/0001193125-26-219422.txt

## Key facts
- Earnings Releases
  Kura Oncology, Inc. reported first quarter ended March 31, 2026 results: revenue $5.8 million.
  - Period: first quarter ended March 31, 2026
  - Revenue: $5.8 million
  - Result: reported results
  source text: identified as being incorporated therein by reference. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Kura Oncology Reports FIRST Quarter 2026 Financial Results – $5.8 million in KOMZIFTITM (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000119312526219422/0001193125-26-219422-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.